Update in carcinoid heart disease - the heart of the matter

Oleinikov, Kira; Korach, Amit; Planer, David; Gilon, Dan; Grozinsky‐Glasberg, Simona

doi:10.1007/s11154-020-09624-y

Cited by 14 publications

(43 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Carcinoid heart disease (CHD) is a serious organ manifestation of patients with carcinoid syndrome and advanced neuroendocrine tumor stage, which lowers the 3-year survival rate to 31% [ 3 , 4 ]. It was first described in 1954 [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

Ablation of typical atrial flutter as therapeutic component in carcinoid heart disease: a case report

et al. 2022

View full text Add to dashboard Cite

Background Carcinoid heart disease is the cardiac manifestation of carcinoid syndrome. There is limited research on rhythm management in patients with carcinoid heart disease. The association of typical atrial flutter and carcinoid heart disease in particular is poorly described. Case presentation Here we present a case of a 77-year-old German woman with carcinoid heart disease and recurrent typical atrial flutter complicating the postoperative course after tricuspid valve replacement and its successful long-term rhythm control by ablation therapy. Conclusion There is limited evidence on rhythm management in patients with the rare diagnosis of carcinoid heart disease. Typical atrial flutter repeatedly complicated the postoperative course of our patient with carcinoid heart disease and could finally be treated curatively by ablation. Radiofrequency ablation should be considered as a valuable therapeutic component in the challenging therapy of this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Ablation of typical atrial flutter as therapeutic component in carcinoid heart disease: a case report

et al. 2022

View full text Add to dashboard Cite

show abstract

“…7,8 Additional imaging is also important in CHD patients with left-sided valvular lesions, which are present in up to 15% of patients with CHD and generally less severe than right-sided valvular involvement. 4 When left-sided valvular lesions are present, an agitated saline contrast echocardiography should be performed to evaluate for a patent foramen ovale, 9 which allows for direct transport of 5-HT to the left side of the heart, bypassing the inactivation that occurs in the pulmonary vascular bed. 3 As our patient continues systemic therapy for advanced CHD, he is planned to undergo a minimally invasive, endoscopic tricuspid valve replacement.…”

Section: Discussionmentioning

confidence: 99%

“…3,4,9,10 Generally, patients with CHD are referred for valve replacement surgery based on the severity of their right heart failure symptoms (e.g., fatigue, dyspnea, edema, ascites) and/or evidence of right ventricular dysfunction on echocardiography. 3,4,9,10 The native valve is usually not repairable in CHD. For any patient with severe and complex valvular disease, evaluation by a multidisciplinary heart valve team is a class I recommendation.…”

Section: Discussionmentioning

confidence: 99%

Delayed Presentation of Carcinoid Heart Disease and Subsequent Modified Healthcare Delivery in the COVID-19 Era

Willauer

Hajjar

Estes

et al. 2022

CASE

View full text Add to dashboard Cite

“…For the diagnosis of carcinoid heart disease, cardiac imaging has a principal role for assessment and monitoring. The first-line imaging modality in carcinoid heart disease evaluation is two-dimensional transthoracic echocardiography (2D TTE), which offers both morphological and functional assessment [132].…”

Section: Carcinoid Syndromementioning

confidence: 99%

Bronchial Carcinoids: From Molecular Background to Treatment Approach

Araujo‐Castro

Pascual‐Corrales

Molina‐Cerrillo

et al. 2022

Cancers

View full text Add to dashboard Cite

A better understanding of the genetic and molecular background of bronchial carcinoids (BCs) would allow a better estimation of the risk of disease progression and the personalization of treatment in cases of advanced disease. Molecular studies confirmed that lungs neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) are different entities; thus, no progression of NET to NEC is expected. In BCs, MEN1 gene mutations and deletions and decreased gene expression have been associated with a poor prognosis. ATRX mutation has also been linked to a shorter disease-specific survival. In terms of therapeutic targets, PI3K/AKT/mTOR pathway mutations have been described in 13% of typical carcinoids (TCs) and 39% of atypical carcinoids (ACs), representing a targetable mutation with kinase inhibitors. Regarding treatment, surgical resection is usually curative in localized BCs and adjuvant treatment is not routinely recommended. Multiple options for systemic therapy exist for patients with advanced BCs, although limited by a heterogeneity in the scientific evidence behind their use recommendation. These options include somatostatin analogues, everolimus, peptide receptor radionuclide therapy, chemotherapy, radiotherapy, antiangiogenic agents, and immunotherapy. In this article, we provide a comprehensive review about the molecular and genetic background of BCs, and about the treatment of local and metastatic disease, as well as the main paraneoplastic syndromes that have been associated with this tumor.

show abstract

Update in carcinoid heart disease - the heart of the matter

Cited by 14 publications

References 69 publications

Ablation of typical atrial flutter as therapeutic component in carcinoid heart disease: a case report

Ablation of typical atrial flutter as therapeutic component in carcinoid heart disease: a case report

Delayed Presentation of Carcinoid Heart Disease and Subsequent Modified Healthcare Delivery in the COVID-19 Era

Bronchial Carcinoids: From Molecular Background to Treatment Approach

Contact Info

Product

Resources

About